Current evidence supports the recommendation of the Global Initiative for Chronic
Obstructive Lung Disease guidelines of at least one of the two classes of long-acting inhaled …

Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting
bronchodilators are now available for use in COPD, but publications of large-scale studies of …

Objective: To review clinical data on the use of long-acting bronchodilator agents as
monotherapy and in combination for the treatment of moderate-to-severe chronic obstructive …

Current guidelines for the management of chronic obstructive pulmonary disease (COPD)
recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids (ICSs) …

Bronchodilators are the mainstay of chronic obstructive pulmonary disease (COPD) therapy.
Inhaled short-acting β2-agonists generally have a more rapid onset of effect and shorter …

The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary
disease (COPD) vary in their pharmacological class (β 2-adrenergic agonist or …

Bronchodilators are the cornerstone of symptomatic treatment for all chronic obstructive
pulmonary disease (COPD) severity stages when administered on a regular basis to prevent …

Since airflow obstruction in chronic obstructive pulmonary disease (COPD) is to some extent
reversible, bronchodilators play an important role in the maintenance treatment of COPD the …

A volume of published evidence sustains the role of long-acting β2-agonists in the treatment
of stable COPD. 1–5 These agents not only induce prolonged bronchodilation, but also …

Study Objective. To assess the comparative efficacy of pharmacologic agents for the
maintenance treatment of chronic obstructive pulmonary disease (COPD). Design …